Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 7Thoracic 6Dermatologic 5Head & Neck 4Gastrointestinal 3Breast 3Other solid neoplasm 1Gynecologic 1

Conditions

Carcinoma, Hepatocellular 29Stomach Neoplasms 13Esophageal Neoplasms 13Colorectal Neoplasms 12Esophageal Squamous Cell Carcinoma 10Rectal Neoplasms 7Pancreatic Neoplasms 7Biliary Tract Neoplasms 7Head and Neck Neoplasms 5Colonic Neoplasms 5Cholangiocarcinoma 5Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 4Locally Advanced Rectal Cancer 4Liver Neoplasms 4Ovarian Neoplasms 3Neoplasms 3Melanoma 3Carcinoma, Renal Cell 3Anus Neoplasms 3Turcot syndrome 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pathologic Complete Response 2Gastric / Gastroesophageal Junction Adenocarcinoma 2Digestive System Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1

Interventions

pembrolizumab 43Nivolumab 29atezolizumab 11Specimen Handling 10Cyclophosphamide 10Bevacizumab 10Paclitaxel 9Magnetic Resonance Spectroscopy 9cabozantinib 7Ipilimumab 7Carboplatin 7fludarabine 6durvalumab 6avelumab 6Sunitinib 6Sorafenib 6Oxaliplatin 6Fluorouracil 6Docetaxel 6spartalizumab 5sargramostim 5Leucovorin 5Cisplatin 5Cetuximab 5aldesleukin 4Trastuzumab 4Radiosurgery 4Psychiatric Rehabilitation 4Irinotecan 4Gemcitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Immune Checkpoint Inhibitors × Gastrointestinal × Clear all
NCT07405086 2026-05-22

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

OHSU Knight Cancer Institute

Phase 4 Recruiting
160 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Bolt Biotherapeutics, Inc.

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡